Early Secukinumab Initiation Tied to Durable Psoriasis Control
A new AJMC-reported analysis links earlier initiation of the IL-17A inhibitor secukinumab to longer-lasting psoriasis control, raising questions about treatment timing.
Topic
Treatment Timing
Topic